Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders, We are thrilled to report that we have successfully launched GraftAssu ...